VIDEO: Margaret Powers, PhD, Speaks About the Impact of Obesity on Chronic Conditions

In this video, Margaret Powers, PhD, talks about obesity's impact on the management of chronic illnesses. Dr. Powers also talks about the benefits of obese patients losing 5% to 7% of body weight and working out 150 minutes a week to lower their risk of developing diabetes and other chronic conditions.

Related Videos

Related Content

Advertisement

November 21st 2024

Semaglutide Eligibility Expands to Over Half of US Adults

Cameron Santoro

Over half of the US adult population may benefit from semaglutide, a drug primarily used for weight loss and diabetes, although concerns about access and cost persist, especially considering its potential for wider health applications.

July 11th 2024

Exploring Pharmaceutical Innovations, Trust, and Access With CVS Health's CMO

Brooke McCormick

On this episode of Managed Care Cast, we're talking with the chief medical officer of CVS Health about recent pharmaceutical innovations, patient-provider relationships, and strategies to reduce drug costs.

November 19th 2024

Community Investment, Engagement Are Essential to Fully Address Cardiovascular Health Disparities

Kyle Munz

Community-based researchers can teach clinicians a lot about how to best approach underserved populations disproportionately impacted by cardiovascular health complications.

August 29th 2023

The Importance of Examining and Preventing Atrial Fibrillation

Maggie L. Shaw

At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.

November 18th 2024

Latest From FINEARTS-HF: No Sex-Specific Differences in Finerenone Outcomes for Heart Failure

Kyle Munz

The FINEARTS-HF trial offered novel clinical insights as one of the few cardiovascular trials to feature such a great proportion of female participants.

November 18th 2024

Cardiomyopathy Risk Plummets When Sacubitril/Valsartan Taken With Chemo

Mary Caffrey

The SARAH trial was limited to high-risk patients, which the lead investigator said prevented unnecessary exposure to adverse events in patients less at risk of cardiomyopathy.

Related Content

Advertisement

November 21st 2024

Semaglutide Eligibility Expands to Over Half of US Adults

Cameron Santoro

Over half of the US adult population may benefit from semaglutide, a drug primarily used for weight loss and diabetes, although concerns about access and cost persist, especially considering its potential for wider health applications.

July 11th 2024

Exploring Pharmaceutical Innovations, Trust, and Access With CVS Health's CMO

Brooke McCormick

On this episode of Managed Care Cast, we're talking with the chief medical officer of CVS Health about recent pharmaceutical innovations, patient-provider relationships, and strategies to reduce drug costs.

November 19th 2024

Community Investment, Engagement Are Essential to Fully Address Cardiovascular Health Disparities

Kyle Munz

Community-based researchers can teach clinicians a lot about how to best approach underserved populations disproportionately impacted by cardiovascular health complications.

August 29th 2023

The Importance of Examining and Preventing Atrial Fibrillation

Maggie L. Shaw

At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.

November 18th 2024

Latest From FINEARTS-HF: No Sex-Specific Differences in Finerenone Outcomes for Heart Failure

Kyle Munz

The FINEARTS-HF trial offered novel clinical insights as one of the few cardiovascular trials to feature such a great proportion of female participants.

November 18th 2024

Cardiomyopathy Risk Plummets When Sacubitril/Valsartan Taken With Chemo

Mary Caffrey

The SARAH trial was limited to high-risk patients, which the lead investigator said prevented unnecessary exposure to adverse events in patients less at risk of cardiomyopathy.